Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

Oncology Clinical Trial

— NET02  

Official title:

A Multi-centre, Randomised, Parallel Group, Open-label, Phase II, Single-stage Selection Trial of Liposomal Irinotecan (Nal-IRI) and 5-fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-line Therapy in Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma (NEC))

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03837977
• Other study ID #: CFTSp116
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: November 13, 2018
• Est. completion date: December 1, 2023

Study information

• Verified date: June 2023
• Source: The Christie NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There is currently no standard treatment beyond first-line etoposide/platinum-based chemotherapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. Therefore the treatment of patients whose disease progresses on or after this first-line treatment is an area of unmet need. Combination regimens such as irinotecan/5-fluorouracil/folinic acid are a second-line treatment option currently used in Europe and world-wide for this subset of patients. However, there is currently no trial evidence supporting this treatment regimen in these patients. Results of the NAPOLI-1 phase III trial of liposomal irinotecan in the treatment of patients with metastatic pancreatic adenocarcinoma after gemcitabine-based therapy reported improved survival for those patients who received a combination of liposomal irinotecan with 5-FU/folinic acid compared to those patients who received 5-FU/folinic acid alone. Liposomal irinotecan has been found to show an improved distribution into tumour tissue in comparison to irinotecan, and this may have clinical benefit in patients with extra-pulmonary neuroendocrine carcinoma. Docetaxel is standardly used as a second-line treatment option in patients with small cell lung cancer who have progressed on primary etoposide-platinum combination therapy. Therefore this drug could also have clinical benefit in patients with extra-pulmonary neuroendocrine carcinoma as the biology of the disease is similar to small cell lung cancer. The overall aim of the NET-02 trial is to select a treatment for continuation to a Phase III trial. The intention of the trial is to determine whether liposomal irinotecan/5-fluorouracil/folinic acid and docetaxel are sufficiently active in this population of patients. If both treatments are found to be efficacious, selection criteria will be applied to select a treatment to take forward. 102 eligible participants will be randomised to receive either liposomal irinotecan/5-fluorouracil/folinic acid given every 14 days, or docetaxel given every 21 days. Participants will be treated for a minimum of 6 months or until discontinuation of treatment as per protocol.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 102
• Est. completion date: December 1, 2023
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18 years and life expectancy =3 months.

2. Diagnosed with poorly differentiated (as defined by the World Health Organisation in 2010, Ki 67 =20%) extra-pulmonary neuroendocrine carcinoma (NEC grade 3, confirmed by histology). (Carcinoma of unknown primary is allowed if lung primary has been excluded following review by the multi-disciplinary team).

3. Prior treatment with first-line platinum-based chemotherapy for NEC in the advanced setting and =28 days from Day 1 of the previous treatment cycle.

4. Documented radiological evidence of disease progression OR discontinuation of first-line platinum-based chemotherapy due to intolerance.

5. Measurable disease according to RECIST 1.1

6. Eastern Co-operative Oncology Group (ECOG) performance status =2

7. Adequate renal function with serum creatinine =1.5 times upper limit of normal (ULN) and creatinine clearance =50ml30ml/min according to Cockroft-Gault or Wright formula. If the calculated creatinine clearance is less than 30 ml/min, glomerular filtration rate (GFR) may be assessed using either Cr51-EDTA or 99mTc-DTPA clearance method to confirm if GFR is =30 ml/min).

8. Adequate haematological function: Hb =90g/L, WBC =3.0 x 109/L, ANC =1.5 x 109/L, platelet count =100 x 109/L.

9. Adequate liver function: serum total bilirubin 1.5 x ULN (biliary drainage is allowed for biliary obstruction) and ALT and/or AST 2.5 x ULN in the absence of liver metastases, or 5 x ULN in the presence of liver metastases.

10. A negative pregnancy test is required at registration in women of childbearing potential.

11. Men and women of reproductive potential must agree to use a highly effective form of contraception during the study and for 6 months following the last dose of trial treatment. In addition, male participants should use a condom during study participation and for 6 months following the last dose of trial treatment.

12. Patients must be able to provide written informed consent.

13. Patients must be able and willing to comply with the terms of the protocol.

Exclusion Criteria:

1. Known or suspected allergy or hypersensitivity reaction to any of the components of study treatment or their excipients.

2. Use (including self-medication) within one week of randomisation and for the duration of the study of any of the following: St. John's wort, grapefruit, Seville oranges, medicines known to inhibit UGT1A1 (e.g. atazanavir, gemfibrozil, indinavir) and medicines known to inhibit or induce either CYP3A4 or CYP3A5

3. Previous treatment (for neuroendocrine carcinoma) with any of the components of combination chemotherapy regimens detailed in this study (nal-IRI or 5-FU or irinotecan or topoisomerase inhibitors or taxane-based therapy).

4. Incomplete recovery from previous therapy in the opinion of the investigator (surgery/adjuvant therapy/radiotherapy/chemotherapy in advanced setting), including ongoing peripheral neuropathy of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 from previous platinum-based therapy.

5. Concurrent palliative radiotherapy involving target lesions used for this study (<28 days from discontinuation of radiotherapy). Radiotherapy for non-target lesions is allowed if other target lesions are available outside the involved field.

6. Patients must not have a history of other malignant diseases (within the previous 3

years, and there must be no evidence of recurrence), other than:

• Extra-pulmonary neuroendocrine carcinoma.
• Non-melanoma skin cancer where treatment consisted of resection only or radiotherapy.
• Ductal carcinoma in situ (DCIS) where treatment consisted of resection only.
• Cervical carcinoma in situ where treatment consisted of resection only.
• Superficial bladder carcinoma where treatment consisted of resection only.

7. Documented brain metastases, unless adequately treated (surgery or radiotherapy only), with no evidence of progression and neurologically stable off anticonvulsants and steroids.

8. Clinically significant gastrointestinal disorder (in the opinion of the treating clinician) including hepatic disorders, bleeding, inflammation, obstruction, or diarrhoea =CTCAE grade 1 (at time of study entry).

9. Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than 6 months before inclusion.

10. New York Heart Association (NYHA) Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure .

11. Severe bone marrow failure or bone marrow depression after radiotherapy or treatment with other antineoplastic agents (defined as haematological values of haemoglobin or white blood cells or neutrophils or platelets not meeting inclusion criteria).

12. Known active hepatitis B virus, hepatitis C virus or HIV infection.

13. Active chronic inflammatory bowel disease.

14. Breastfeeding women.

15. Evidence of severe or uncontrolled systemic diseases which, in the view of the treating clinician, makes it undesirable for the patient to participate in the trial.

16. Evidence of significant clinical disorder or laboratory finding which, in the opinion of the treating clinician, makes it undesirable for the patient to participate in the trial.

17. Medical or psychiatric conditions that impair the ability to give informed consent.

18. Any other serious uncontrolled medical conditions (in the opinion of the treating clinician).

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Neuroendocrine
• Neuroendocrine Carcinoma
• Oncology

Intervention

Drug:
• Liposomal Irinotecan
Arm I
• Fluorouracil
Arm I
• Folinic Acid
Arm I
• Docetaxel
Arm II

Locations

Country	Name	City	State
United Kingdom	The Beaston West of Scotland Cancer Center, NHS Greater Glasgow and Clyde	Glasgow
United Kingdom	Hammersmith Hospital, Imperial College Healthcare NHS Trust	London
United Kingdom	The Christie NHS Foundation Trust	Manchester
United Kingdom	Weston Park Hospital, Sheffield Teaching Hospitals, NHS Trust	Sheffield

Sponsors (4)

Lead Sponsor	Collaborator
The Christie NHS Foundation Trust	National Institute for Health Research, United Kingdom, Servier, University of Leeds

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival defined as a binary outcome (progression-free or not)		treatment start date until 6 months, assessed at 8 weekly intervals by CT scan
Secondary	Progression-free survival defined as time from randomisation to progression or death from any cause.	Individuals will be censored if they are lost to follow-up or still alive and progression-free at the time of analysis.	randomisation until 6 months after the last participant is randomised (end of trial), assessed at 8 weekly intervals by CT scan and death is continuously assessed
Secondary	Overall survival defined as time from randomisation to death from any cause.	Individuals will be censored if they are lost to follow-up or still alive and progression-free at the time of analysis.	randomisation until 6 months after the last participant is randomised (end of trial), death is continuously assessed
Secondary	Objective response rate defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.		start of treatment until 6 months after the last participant is randomised (end of trial)
Secondary	Toxicity defined as the number of participants with treatment-related adverse events as assessed by common terminology criteria for adverse events (CTCAE) v5.0.		treatment start date until 6 months after the last participant is randomised (end of trial), assessed at 2 (nal-IRI/5-FU/folinic acid) or 3 (docetaxel) weekly intervals
Secondary	Quality of life assessed according to the patient reported outcome measures; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30		randomisation until 6 months after the last participant is randomised (end of trial), assessed at 6 weekly intervals
Secondary	Neuron-specific enolase (NSE) measurements.		baseline until 6 months after the last participant is randomised (end of trial), assessed at 6 weekly intervals
Secondary	Quality of life assessed according to the patient reported outcome measures; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) GINET21.		randomisation until 6 months after the last participant is randomised (end of trial), assessed at 6 weekly intervals